Enveda reported Phase 1 results for ENV-308, an oral compound designed to mimic exercise effects by targeting leptin biology and potentially preserving lean mass during weight loss. The company said it aims to reduce a common challenge seen with GLP-1 receptor agonists: gastrointestinal intolerance and lean-mass loss during cycling on and off therapy. ENV-308 is based on lactate phenylalanine (lac-phe), a small-molecule metabolite discovered by Stanford scientists and reported in Nature (2022) to suppress appetite and lower obesity in animals. Both lac-phe and ENV-308 are described as acting on leptin, positioning the candidate as a potential “leptin sensitizer in a pill.” While the announcement centers on early safety and preliminary signals, Enveda framed the program around clinical follow-through needed to demonstrate durable weight loss alongside maintenance of muscle mass. If confirmed, the approach would offer an oral alternative aimed at addressing two patient concerns linked to long-term obesity pharmacotherapy.